New York A 6222: Relates to establishing an electronic registration process

Bill Text

Bill Search and Legislative Information | New York State Assembly 

• 

• 

• 

• 

• 

• 

• 

• 

 Skip to main content 

 New York State Assembly

 Speaker Carl E. Heastie

 --> 
 --> 

 --> 

• 
 Assembly Members 

• 
 Legislative Info 

• 
 Public Hearings 

• 
 Speaker's Press 

• 
 Assembly Reports 

• 
 Committees & More 

• Bill Search Home
• Laws
• Legislative Calendar
• Public Hearing Schedule
• Assembly Calendars
• Assembly Committee Agenda 

 Javascript must be enabled to properly view this page. 

 Bill No.: 

• Summary 
• Actions 
• Committee&nbspVotes 
• Floor&nbspVotes 
• Memo 
• Text 
• LFIN 
• Chamber&nbspVideo/Transcript 
A06222 Summary:

BILL NOA06222 

&nbsp

SAME ASSAME AS S01913

&nbsp

SPONSORPaulin

&nbsp

COSPNSRSimone, Rosenthal, Simpson, Taylor, Simon, Gonzalez-Rojas, Shimsky, Lunsford, Lemondes, Zaccaro,
 Bronson, Griffin, Meeks, Woerner, Sayegh, Hevesi, Weprin, Lupardo, Kelles, Burroughs, Forrest,
 Kassay, Gibbs, Levenberg, Wright, Shrestha, Davila, Dinowitz, Cruz, Lavine, Hooks, Rozic, Reyes,
 Schiavoni, Ramos, Stirpe, Lee, Carroll R, Rivera, Stern, Cashman, Burdick, Brown K, Kay, Beephan,
 Manktelow

&nbsp

MLTSPNSR

&nbsp

Add §280-d, Pub Health L

&nbsp

Relates to establishing the "340B prescription drug anti-discrimination act"; prohibits pharmaceutical manufacturers and pharmacy benefit managers from discriminating against covered entities and New York state pharmacies based on participation in the drug discount program authorized by section 340B of the federal public health service act.

Go to top A06222 Actions:

BILL NOA06222 

&nbsp

02/27/2025referred to health

01/07/2026referred to health

Go to topA06222 Committee&nbspVotes:

Go to topA06222 Floor&nbspVotes:

There are no Assembly votes for this bill in this legislative session.

Go to topA06222 Text:

 STATE OF NEW YORK
 ________________________________________________________________________

 6222

 2025-2026 Regular Sessions

 IN ASSEMBLY

 February 27, 2025
 ___________

 Introduced by M. of A. PAULIN, SIMONE, ROSENTHAL, SIMPSON, TAYLOR,
 SIMON, GONZALEZ-ROJAS, SHIMSKY, SANTABARBARA, LUNSFORD, LEMONDES,
 ZACCARO -- read once and referred to the Committee on Health

 AN ACT to amend the public health law, in relation to establishing the
 340B prescription drug anti-discrimination act

 The People of the State of New York, represented in Senate and Assem-
 bly, do enact as follows:

 1 Section 1. Short title. This act shall be known and may be cited as
 2 the "340B prescription drug anti-discrimination act".
 3 § 2. The public health law is amended by adding a new section 280-d to
 4 read as follows:
 5 § 280-d. Prescription drug discrimination prohibited. 1. Definitions.
 6 (a) "340B program" shall mean the drug discount program authorized by
 7 section 340B of the federal public health service act (42 U.S.C. §
 8 256b).
 9 (b) "Covered entity" shall have the same meaning as is set forth in
 10 section 340B(a)(4) of the federal public health service act (42 U.S.C. §
 11 256b).
 12 (c) "Contract pharmacy" shall include New York state pharmacies that
 13 receive drugs purchased under a contract pharmacy arrangement with a
 14 covered entity.
 15 (d) "Dispensing" shall include a pharmacy's entire distribution proc-
 16 ess, including, but not limited to, the ordering, purchasing, deliver-
 17 ing, receipt, and sale of drugs.
 18 (e) "Pharmacy" shall have the same meaning as is set forth in section
 19 sixty-eight hundred two of the education law.
 20 2. Prohibition of discriminatory practice. No pharmaceutical manufac-
 21 turer, pharmacy benefit manager, outsourcing facility, or third-party
 22 logistics provider shall directly or indirectly:
 23 (a) deny, prohibit, condition, or otherwise limit the dispensing of
 24 drugs from a covered entity or contract pharmacy, other than such limi-

 EXPLANATION--Matter in italics (underscored) is new; matter in brackets
 [ ] is old law to be omitted.
 LBD03887-02-5

 A. 6222 2

 1 tations explicitly identified or explicitly authorized either under
 2 section 340B of the federal public health service act (42 U.S.C. §
 3 256b), or any regulations promulgated pursuant to such statute;
 4 (b) deny access to drugs manufactured by a pharmaceutical manufacturer
 5 to a covered entity or contract pharmacy based on such covered entity's
 6 or contract pharmacy's participation in the 340B program; or
 7 (c) impose requirements, exclusions, reimbursement terms, fees,
 8 audits, claim identification, or other conditions on a covered entity or
 9 contract pharmacy that differ from the requirements, exclusions,
 10 reimbursement terms, fees, audits, claim identification, or other condi-
 11 tions applied to entities that do not participate in the 340B program,
 12 other than such limitations explicitly identified or explicitly author-
 13 ized either under section 340B of the federal public health service act
 14 (42 U.S.C. § 256b), or any regulations promulgated pursuant to suc